Recent literature suggested that cells of the microenvironment of tumors could be abnormal as well. To address this hypothesis in multiple myeloma (MM), we studied bone marrow mesenchymal stem cells (BMMSCs), the only long-lived cells of the bone marrow microenvironment, by gene expression profiling and phenotypic and functional studies in three groups of individuals: patients with MM, patients with monoclonal gamopathy of undefined significance (MGUS) and healthy agematched subjects. Gene expression profile independently classified the BMMSCs of these individuals in a normal and in an MM group. MGUS BMMSCs were interspersed between these two groups. Among the 145 distinct genes differentially expressed in MM and normal BMMSCs, 46% may account for a tumor-microenvironment cross-talk. Known soluble factors implicated in MM pathophysiologic features (i.e. IL (interleukin)-6, DKK1) were revealed and new ones were found which are involved in angiogenesis, osteogenic differentiation or tumor growth. In particular, GDF15 was found to induce dosedependent growth of MOLP-6, a stromal cell-dependent myeloma cell line. Functionally, MM BMMSCs induced an overgrowth of MOLP-6, and their capacity to differentiate into an osteoblastic lineage was impaired. Thus, MM BMMSCs are abnormal and could create a very efficient niche to support the survival and proliferation of the myeloma cells.
Introduction
The tumor-associated microenvironment constitutes a permissive milieu for the induction, selection and expansion of cancer cells. [1] [2] [3] Conversely, neoplastic cells may modify the microenvironment through cell communication proteins, in particular growth factors. Genetic profiling of solid tumors has shown abnormal gene expression in both cancer cells and cells from the microenvironment. 4 The result is a vicious circle, whereby each cell type contributes to the growth of the tumor. Elucidating the role of the microenvironment is a major concern in finding ways to disrupt this vicious circle and induce cancer cell apoptosis.
Multiple myeloma (MM) is a B-cell neoplasia that affects 2000 new patients per year in France, 15 000 in Europe and 15 000 in the United States. This disease is still fatal, with a median survival rate of 4.6 years. 5, 6 MM is characterized by the proliferation of a malignant plasma cell clone, initially located in the bone marrow microenvironment (BMMe). This illness is unique among hematological malignancies in its capacity to cause great bone destruction, leading to pathologic bone fractures and intractable bone pain. This result is the consequence of an imbalance between osteoblastic and osteoclastic activity induced by MM cells. 7 Impaired osteoblastic function may be the consequence of a direct action on the osteoblasts, since MM cells enhance their apoptosis. 8, 9 MM cells may also block the differentiation of bone marrow mesenchymal stem cells (BMMSCs) into osteoblasts, by producing the Wnt inhibitors DKK1 or sFRP2 10, 11 or the EGF family member amphiregulin. 12 The BMMe is a complex network of extracellular matrix and at least four cell partners, namely osteoclasts, cells of mesenchymal origin, lymphoid cells and endothelial cells. Osteoclasts and endothelial cells were shown to provide efficient support for MM cell survival and proliferation. Indeed, BMMSCs strongly support MM cell growth, 13 producing a high level of interleukin (IL)-6, a major MM cell growth factor. 14 BMMSCs also support osteoclastogenesis and angiogenesis. [15] [16] [17] [18] Previous studies suggested that the BMMSCs in MM differ from those of healthy donors. 19, 20 In particular, MM BMMSCs expressed less CD106 and fibronectin, and 2.8 times more IL1b as compared with normal BMMSCs 21 and showed abnormal synthesis of hyaluronan. 22, 23 Taken together, these data suggest that MM BMMSCs differ from their normal counterparts. To address this question, we conducted studies in three complementary directions: gene expression profile (GEP) with microarray analysis, phenotypic and functional studies. We compared three groups of individuals: MM patients, patients with monoclonal gamopathy of unknown significance (MGUS) and healthy age-matched subjects. GEP was able to discriminate BMMSCs in MM and healthy subjects, with MGUS BMMSC genes distributed between these two groups. We found 145 genes and 18 ESTs differentially expressed between normal and MM BMMSCs. Among the 127 genes annotated with Gene Ontology, 46% corresponded to molecules potentially involved in the tumor microenvironment. Functionally, MM BMMSCs were as potent as their normal counterparts in supporting the growth of hematopoietic stem/ progenitor cells. They induced an overgrowth of a stromal celldependent myeloma cell line. Finally, their capacity to differentiate into an osteoblastic lineage was impaired. informed consent. We selected 10 patients with stage-I and 12 with stage-III MM. Patients' characteristics are shown in Table 1 . Eleven healthy people who were allogeneic bone marrow donors or were undergoing total hip replacement surgery and gave their informed consent were also included. These healthy donors had the same age range as the patients with MM (Table 1 ).
Cells
Bone marrow from patients was obtained by sternal puncture. Marrow from healthy individuals was obtained from filters used during the preparation of the allogeneic hematopoietic grafts or from tiny bony fragments obtained during the hip surgery. For the primo-culture (P0), bone marrow cells were cultured (at 5 Â 10 4 cells/cm 2 ) in aMEM þ 10% fetal calf serum (FCS) þ 10 mg/ ml of ciprofloxacin used as an antibiotic. After 3 days in culture, nonadherent cells were harvested, and medium was replaced by fresh medium. Then the cultures were fed two times a week until confluence or until 21 days. BMMSCs were detached using trypsin (InVitrogen, Cergy-Pontoise, France) and counted using trypan blue exclusion. They were cultured once, at 10 3 cells/ cm 2 , under the same conditions (first passage, P1). BMMSCs at P0 or P1 were used immediately or frozen until use. The BMMSCs expansion was calculated as the total number of cells at the end of P1 divided by that at P1 start.
To evaluate the frequency of colony-forming unit-fibroblast (CFU-F), fresh bone marrow cells were seeded at 2 Â 10 4 cells/ cm 2 , P0 cells at 8 cells/cm 2 and P1 cells at 16 cells/cm 2 for 11 days as indicated above. Culture vessels were then washed with phosphate-buffered saline, fixed with methanol and stained with Giemsa (Oxoid, Dardilly, France), and colonies with more than 50 cells were counted. CD34 þ cells from two granulocyte colony stimulating factor (G-CSF)-mobilized patients were purified (9072% purity) using a MACS system (Miltenyi Biotec, Paris, France) according to the manufacturer's recommendations and frozen until use.
The XG-1 myeloma cell line 24 was cultured in RPMI-1640 medium with 10% FCS, ciprofloxacin and IL-6 (2 ng/ml, R&D Systems, Lille, France). The MOLP-6 cell line, a generous gift of Dr Harashima, 25 was grown on bone marrow stromal cells in RPMI-1640 with 10% FCS and ciprofloxacin.
Differentiation of BMMSCs into osteoblasts
BMMSCs (after P0 or P1) were seeded at 10 4 cells/cm 2 in 96-, 24-or 12-well culture plates in the culture medium plus 0.1 mM dexamethasone and 50 mg/ml ascorbic acid (Sigma, Lyon, France). For mineralization study, 3 mM of inorganic phosphate (Sigma, France) was also added. Medium was changed twice a week. Cultures were stopped after 21 days. Then, alkaline phosphatase activity was assessed qualitatively and quantitatively by fast violet staining and using Attophos (Promega, Charbonnières, France), respectively, and mineralization by von Kossa staining 26 and alizarine red staining, as described by Gregory.
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Co-culture of BMMSCs and CD34 þ cells P1 frozen BMMSCs were thawed and put in 12-well plates in duplicate at 5000 cells/cm 2 in 1 ml of culture medium. After 24 h, the wells were emptied, and 4 Â 10 4 CD34 þ cells were seeded in each well in 2 ml Myelocult medium containing 10 mM hydrocortisone (Stem Cell Technologies, Grenoble, France). At 7, 14, 21 and 28 days, half of the medium with nonadherent cells was replaced by fresh Myelocult medium with hydrocortisone. The cells in the supernatant were counted and assayed for hematopoietic progenitors in methyl-cellulose (Miltenyi Biotec, France). At the end of the co-culture (day 35), the cells in suspension and adhering to the BMMSCs were assayed for hematopoietic progenitors. The total number of clonogenic progenitors was calculated (number of colonies Â total number of cells in the co-culture/number of seeded cells in methyl-cellulose).
Co-culture of BMMSCs and myeloma cell lines XG-1: BMMSCs were seeded in 12-well plates in quadruplicate at 11250 cells/cm 2 in 1 ml of culture medium. After 24 h of culture, the medium was eliminated, and 31250 XG-1 cells were added to each well in 1 ml of RPMI 1640 þ 10% FCS. For each sample, two of the four wells received 10 mg/ml of a neutralizing anti-IL-6 antibody. 28 For each condition, the number of XG-1 cells was evaluated at days 4 and 7.
MOLP-6: BMMSCs were seeded in 12-well plates in quadruplicate at 11250 cells/cm 2 in 1 ml of culture medium. After 24 h of culture, the medium was eliminated and 20 000 MOLP-6 cells were added in each well in 1 ml of RPMI 1640 þ 10% FCS. The number of MOLP-6 cells was evaluated at days 4 and 7.
Flow cytometry
BMMSCs were phenotyped by flow cytometry with FITC-or phycoerythrin-conjugated anti-CD90, anti-CD45, anti-CD13, anti-CD14 (Beckman-Coulter, Villepinte, France) and anti-CD73 (Becton-Dickinson, Le Pont de Claix, France) monoclonal antibodies (MoAb). Fluorescence was analyzed using a FACScan flow cytometer (Becton-Dickinson).
Enzyme linked immunosorbent assay
The concentration of the following molecules was evaluated in the culture supernatant of BMMSCs using a commercial enzyme-linked immunosorbent assay (ELISA) kit (R&D systems): IGF-1, IL-1b, IL-6, GDF15, SDF-1 and amphiregulin. DKK1 concentration was assessed with use of in-house ELISA with anti-mouse IgG-coated microplates. The capture DKK1 antibody (mouse MoAb to human DKK1, R&D Systems) was incubated for 1 h. After 3 washings, culture supernatants or standards (DKK1 concentrations ranging from 0 to 20 ng/ml) were incubated for 2 h. After three washings, the detection antibody (biotinylated goat anti-human DKK1) was incubated for 2 h. After three washings, the HRP-labeled streptavidin was added to each well and incubated for 20 min. After three additional washings, the substrate was added and incubated for 20 min in the dark; then 50 ml of the stop solution was added and the plate was gently agitated. Optical density was read at 450 nm using a microplate reader.
Microarrays
At the end of P1, the mRNA of BMMSCs from seven healthy donors, five patients with MGUS and six with MM was extracted using the RNeasy Kit (Quiagen, Hilden, Germany). Biotinylated cRNA synthesis, hybridization to human U133 plus 2.0 GeneChip microarrays (54 675 probe sets for approximately 39 000 genes, Affymetrix, Santa Clara, CA, USA) and analysis were performed as described previously.
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Real-time RT-PCR analysis
Complementary DNA was obtained from 2 mg of total RNA using Superscript II reverse transcriptase (Life Technologies) and oligo d(T) [12] [13] [14] [15] [16] [17] [18] (Amersham Pharmacia Biotech, Orsay, France) as a primer. We used the assay-on-demand primers and probes and the TaqMan Universal Master Mix from Applied Biosystems (Courtaboeuf, France) according to the manufacturer's instructions. Gene expression was measured by using the ABI Prism 7000 Sequence Detection System. For comparative analysis of gene expression, data were obtained by the DDC t method derived from a mathematical approach. For each sample, the C T value for the gene of interest was determined, normalized to its respective C T value for GAPDH (DC T ¼ C T -C T GAPDH) and compared with one BMMSC sample used as a positive control. The formula used was sample À DC T control cell line. C T values were collected during the log phase of the cycle. The results were expressed as the relative mRNA level to control cell mRNA.
Statistical analysis
Scanned data were uploaded into our RAGE bioinformatics facility (http://rage.montp.inserm.fr). Probe sets that were not expressed in at least one sample using the Absent/Present 'Call detection' algorithm (MAS5/GECOS software from Affymetrix 29 ) were discarded. To compare normal and MM BMMSCs, we performed an unsupervised classification with both principal component analysis (PCA) for optimal cluster detection and hierarchical clustering with information on gene co-expression. 30 The principal component analysis involved original scripts based on the R statistics software through the RAGE web interface. In a two-scale representation, the separation between groups was indicated by the angle between sample vectors, which must be the smallest among classes for homogeneity but the highest between classes to ensure an optimal separation. Hierarchical clustering involved use of the Cluster and TreeView softwares (http://rana.lbl.gov/EisenSoftware.htm). GEP were analyzed by use of the RAGE supervised analysis module using non-parametric Mann-Whitney U-test with multiple testing correction and confirmed with the Significance Analysis of Microarrays (SAM) software (http://www-stat.stanford.edu/~tibs/ SAM/). The Gene Ontology annotation of the differentially expressed genes was performed with the Fatigo platform (http:// fatigo.bioinfo.cnio.es/). Significant relative enrichment of Gene Ontology categories of relevant genes was assessed using Gene Ontology Tree Machine (GOTM, http://bioinfo.vanderbilt.edu/ gotm). Hypergeometric test was used to calculate the statistics for each category. Statistical comparisons of other data involved the Mann-Whitney test, Kruskall-Wallis ANOVA, Spearman correlation and Student's t-test (CSS Statistica, Statsoft, MaisonsAlfort, France).
Results

BMMSC phenotype, growth characteristics and hematopoietic support
BMMSCs were selected by adherence on plastic vessels. The cells from 11 healthy donors were compared with those from 22 MM patients (10 stage I and 12 stage III) and from seven MGUS patients. BMMSCs from the three groups of subjects were positive for CD13, CD73, CD90 but lacked CD45 and CD14. Data of normal or MM BMMSCs are shown in Figure 1a . As the BMMSCs proliferation is correlated with age of donors, we have chosen normal donors who were age matched with the MM patients ( Table 1 ). The CFU-F concentration in bone marrow did not differ among the three groups of subjects (Table 2) . Cell density in the cultures at P0 and P1 did not differ among groups. As a result, BMMSCs expansion was not different among the three groups of subjects (26.573.4-fold, 28.976.4-fold and 25.373.7-fold, respectively, for normal, MGUS and MM). We did not observe any differences between stage I and stage III MM. MM and normal BMMSCs did not differ significantly in their long-term ability to support hematopoietic stem/progenitor cell growth, as shown in Figure 1b . The total number of GM-CFU generated in the cultures did not significantly differ when either normal or MM BMMSCs were used as hematopoietic stem cell support.
Genetic expression profiles distinguish normal BMMSCs from MM BMMSCs
The genetic profile of seven BMMSCs from normal donors, six BMMSCs from patients with stage III MM and five BMMSCs from MGUS patients was determined by Affymetrix microarrays. We have chosen stage III MM patients to maximize the potential At a VC of 60%, the separation was the best and includes B2 000 genes. Inset in the lower left corner of the figure: tree from the hierarchical clustering analysis on the same group of probe sets. All data are expressed as mean7s.e.m.
Multiple myeloma MSC are abnormal J Corre et al differences with normal subjects. Unsupervised analysis using a high variation coefficient (X60%) between samples was first performed on normal and MM BMMSCs, delineating 2008 probe sets expressed at least once (present call) across the samples. The signal data from normal, MGUS and MM BMMSCs, obtained with this probe set list, were then subjected to principal component analysis for an optimal dimensionality reduction and cluster detection. Two groups of samples were distinguished -a rather tight MM BMMSC cluster (termed MSCMMZ in the figure) as shown by the small angular dispersion of the MM samples, and a normal BMMSC one (termed MSCNOR, Figure 2 ). MGUS BMMSCs interspersed between the 'MM cluster' and the 'normal cluster' (MSCGUS, Figure 2 ). A hierarchical clustering was performed with the same data and confirmed the PCA analysis ( Figure 2 , inset in lower left corner). A hierarchical clustering heatmap is shown in Supplementary Figure and provides information on gene coexpression. These results suggest that microarrays could pinpoint differences between MM and normal BMMSCs.
Comparison of gene expression between malignant and normal BMMSCs
We then used supervised analysis to investigate the genes differentially expressed between MM and normal BMMSCs. Signal data from the two classes were filtered according to the ratio of the means of expression values in each sample group and subjected to a Mann-Whitney non-parametric rank test as described previously. 31 A total of 183 significant probe sets were differentially expressed between normal and MM BMMSCs (at least one presence, ratio of means of expression X2, or p0.5, Pp0.01). The false discovery rate was determined using 1000 permutations of the samples, giving a median false positive number of 20 probe sets out of 183 and, therefore, a false discovery rate of 10.9%. We also performed a supervised analysis using SAM software on the same samples with onepresence and 2-ratio filters and 500 permutations, which resulted in a list of 330 probe sets, with a false discovery rate of 10.5% (34/330 probe sets). This list encompassed all of the 183 (100%) probe sets selected through the first supervised comparison. This 183-probe set list represents 145 distinct genes and 18 ESTs (163 genes/ESTs, available as Supplementary Table  1 ). Twenty noteworthy genes are shown in Table 3 . A total of 94 genes/ESTs were overexpressed in MM BMMSCs. Of these 163 genes/ESTs, 127 were annotated. Of note, 46% (59 out of 127) were classified in a 'tumor environment' category. These 46% tumor-environment genes encode for cell communication proteins (27%), receptor signalization molecules (11%), and extracellular matrix or secreted molecules (9%). The other functions were metabolism, nuclear function, cytoskeleton, protein synthesis, cell cycle, and apoptosis (Supplementary  Table) . Using GOTM web platform, we have found that the categories: extracellular region, receptor binding, cytokine activity and cell adhesion were enriched 2.6 times (23 genes, P ¼ 0.0001), 2.3 times (11 genes, P ¼ 0.008), 4.2 times (7 genes, P ¼ 0.0014) and 2.3 times (11 genes, P ¼ 0.0087), respectively. This reinforced our manual classification. Some of these genes encode for growth factors reported to be involved in MM. Amphiregulin (AREG), a member of the EGF family, and IL-1b were overexpressed in MM BMMSCs as compared to normal BMMSCs, in a ratio of 2.8 and 3.5, respectively. These data were validated at the mRNA level by real-time RT-PCR or at the protein level by ELISA (Figure 3) . Although IL-1b secretion was 16 times higher for MM BMMSCs, the difference was not significant, probably because of the low number of samples studied and the low level of secretion. AREG concentration was under the sensibility threshold for our ELISA test. The DKK1 mRNA level was increased by 2.4 times in MM BMMSCs and the protein was increased by 1.4 times in the culture supernatant ( Figure 3 ). IGF-1 and SDF-1 were underexpressed in MM BMMSCs as compared to normal BMMSCs, in a ratio of 5.5 and 3, respectively. Data were validated with real-time RT-PCR. In Table 3 Differentially interesting expressed genes Those 20 genes are highlighted here because (i) either they have already been described to be involved in the biology of MM or (ii) data from the literature suggest that they might have important biological function in MM but they have never been directly involved in myeloma pathogenesis (see discussion section).
Multiple myeloma MSC are abnormal J Corre et al addition, the concentration of SDF-1 in the supernatant of MM BMMSCs represented 40% of the level found in normal BMMSC supernatant. The level of secreted IGF-1 was under the sensitivity threshold of ELISA test. We also tested the concentration of IL-6 in culture supernatant, because this molecule is important in MM pathophysiologic features and its mRNA level is increased in BMMSCs, although the level (1.9, Po0.02) did not reach our limit of twofold increase. MM BMMSCs secreted 2.4 times more IL-6 than normal BMMSCs (7.3 Â 10 À1 71.7 Â 10
À1
pg/cell versus 3 Â 10 À1
Â 10
À2 pg/cell, respectively, Po0.03). There was good correlation between the IL-6 mRNA level measured by microarray and the IL-6 concentration in the culture supernatant (R ¼ 0.9, Po0.001).
We also discovered some genes never described in MM, such as growth and differentiation factor 15 (GDF15), increased in MM BMMSCs. Both GDF15 mRNA and secreted protein levels were four-fold higher in MM BMMSCs as compared with normal BMMSCs and differences were significant (Figure 4a ). The effect of GDF15 was tested on the growth of the stromal celldependent MOLP-6 myeloma cells. Without the addition of stromal cells, MOLP-6 cells progressively underwent apoptosis. GDF15 could replace stromal cells, supporting long-term MOLP-6 growth in a dose-dependent manner (P ¼ 0.04) (Figure 4b) . A concentration of 100 ng/ml of GDF15 increased three fold the MOLP-6 cell number in 5-day cultures. GDF15 had no effect on XG-1 cell line even when associated with a suboptimal dose of IL-6.
Increased proliferation of the MOLP-6 myeloma cell line cocultured with MM BMMSCs as compared to normal BMMSCs
As MM BMMSCs have a distinct genetic profile as compared with normal BMMSCs, we investigated their ability to support MM cell growth using the MOLP-6 stromal cell-dependent Figure 3 Expression of mRNA and protein secretion by normal or MM BMMSCs mRNA expression levels obtained either from U133P 2 þ microarrays (diamond symbols~) or from qRT-PCR (square symbols ') and protein secretion (pg/cell) from ELISA (circle symbols K) are plotted according to subject status (healthy subjects ¼ plain symbol, MM patients ¼ empty symbol). For each measure, the arithmetic mean is represented by a straight line. Significant differences between healthy subjects and MM patients are indicated by * (Po0.05) or y (Po0.001).
Multiple myeloma MSC are abnormal J Corre et al myeloma cell line and the XG-1 stromal cell-independent but IL-6-dependent cell line. Of interest, MM BMMSCs supported MOLP-6 better than normal BMMSCs after 7 days of culture (3.370.4-fold vs 2.270.3-fold amplification, P ¼ 0.04). The proliferation of the stromal cell-independent but IL-6-dependent XG-1 myeloma cells was supported equally efficiently by normal and MM BMMSCs (Table 4) and was abrogated by adding an anti-IL-6 monoclonal antibody. Although MM BMMSCs produced higher amounts of IL-6 than normal BMMSCs, this lack of difference in supporting XG-1 growth is understandable because normal BMMSCs produced enough IL-6 to induce maximal proliferation of XG-1 cells that are highly sensitive to IL-6.
BMMSC osteoblastic differentiation
As osteoblastic function is impaired in advanced myeloma, we checked the differentiation of BMMSCs into the osteoblastic lineage. The qualitative assessment of phosphatase activity did not differ between normal and MM BMMSCs (data not shown). However, matrix mineralization of MM BMMSCs, as assessed by von Kossa staining, was qualitatively less abundant than that obtained with normal BMMSCs (Figure 5a ). We used quantitative technique to measure both phosphatase activity and mineralization. After 21 days of differentiation, the phosphatase activity ratio for normal BMMSCs did not differ significantly from that of MM BMMSCs (2.570.3 vs 370.5). In one experiment, we quantified matrix mineralization for two normal and three MM BMMSCs and found a striking reduction in matrix mineralization for MM BMMSCs (Figure 5b ).
Discussion
The aim of this study was to investigate the differences in BMMSCs from normal donors and from patients with newly diagnosed myeloma. The bone marrow of MM patients showed a normal frequency of CFU-F and a proliferation rate equivalent to normal BMMCs. The ability to support the growth of hematopoietic stem cells did not differ between normal and MM BMMSCs. A remarkable finding is that MM BMMSCs had a distinctive GEP on microarray analysis. Indeed two unsupervised methods could classify genes in BMMSCs from MM patients into an MM cluster and those from normal age-related donors into a normal cluster. Even more remarkable is that these BMMSCs have a specific gene signature, even if they have been cultured in vitro for 41 days in the absence of malignant plasma cells (cells are (10, 50 and 100 ng/ml). After 7 days, the cells were counted by trypan blue exclusion, and the expansion coefficient was calculated (d7 cell number/d0 cell number). MOLP-6 expansion with 100 ng/ml of GDF15 was three times greater than that without GDF15 (n ¼ 7, R ¼ 0.38 and P ¼ 0.048) More than 140 genes were differentially expressed between normal and MM BMMSCs. Study of their ontology revealed that almost half may participate in the support of malignant plasma cells; thus, we called them 'tumor microenvironment' genes. The cell communication molecules represented 27% of the genes and are likely involved in the communication with myeloma cells. The factors IL-1b, AREG, IL-6 and DKK1 had already been described to be positive key factors in the biology of myeloma. 33 IL-1b, AREG and DKK1 are also secreted by the malignant plasma cells. 10, 12, 34, 35 They could either directly favor their survival like AREG (12) or enhance IL-6 secretion like IL-1b and DKK1. 35, 36 Thus, the expression of these factors, at the same time by the cells of the microenvironment and the malignant plasma cells, could better ensure the survival of the tumor cells thanks to an amplification loop.
Of interest, we also identified genes coding for proteins that have never been directly implied in MM. One group could be, in part, responsible for the development of angiogenesis by increasing the imbalance between the pro-and anti-angiogenic factors. 37 Angiopoietin-like 4 (ANGPTL4), plasminogen activator inhibitor 1 (PAI-1) and secretrogranin II (SCG2) were overexpressed 4.5, 2.6 and 2.6 times, respectively, by the MM BMMSCs. ANGPTL4 is an angiogenic factor, independent of VEGF, whose production is mediated by PPAR-g. 38 PAI-1 has been reported to control key aspects of angiogenesis and, in turn, tumor progression through its anti-proteolytic activity. 39 Stromal cell production of PAI-1 has been reported to be more important for its action than cancer cell production.
40 SCG2 belongs to a family of the chromogranins and is the precursor of secretoneurin, which is both a pro-angiogenic and a chemotactic factor for monocytes and endothelial cells. 41 In vivo, secretoneurin mobilizes the endothelial progenitors and supports their integration in the newly formed vessels. IL-17D, recently discovered, belongs to a family of inflammatory cytokines, which includes six members (IL-17A-17F). We found that the MM BMMSCs overexpressed IL-17D. IL-17D induces the secretion of IL-6 by endothelial cells and inhibits, in vitro, the proliferation of the myeloid progenitors. 42 Another group of molecules, underexpressed by MM BMMSCs as compared to normal BMMSCs, is involved in bone physiology and may explain in part the osteoblast anomalies. We observed a 3.6-, three-and two-fold decrease in mRNA expression of the C receptor of natriuric peptide (NPR3), Wnt-1-induced secreted protein 1 (WISP-1) and endothelial differentiation gene 2 (EDG2), respectively. NPR3 is considered to be responsible for the clearance of the ANPs and thus the modulation of their effects. NPR3-knockout mice show abnormalities of the skeleton, in particular a defect of endochondral ossification. 43 WISP-1 belongs to the CCN family and has been shown to support BMP-2-induced osteoblastic differentiation. 44 In vivo, in a model of fracture, WISP-1 is expressed in mesenchymal cells that surround the site of the injury. EDG2 is one receptor for lysophosphatidic acid (LPA), which is involved in osteoblast proliferation and prevents their apoptosis. 45, 46 EDG2 mutant mice displayed skeletal abnormalities. 47 Finally, we have shown for the first time, both at the mRNA and protein level, that GDF15 expression was higher in MM BMMSCs than in normal BMMSCs and that GDF15 is a growth factor for the MOLP-6 stromal cell-dependant myeloma cell line. GDF15 is a divergent member of the TGFb superfamily. 48 In normal human subjects, it is highly expressed in the placenta and its serum concentration increases during pregnancy. 49 GDF15 concentration is increased in the serum of patients with prostate, colorectal or pancreatic cancers 50, 51 and was recently described as one of the 20 best biomarkers of numerous tumors. 52 In vitro, GDF15 prevents the apoptosis of cerebellar Multiple myeloma MSC are abnormal J Corre et al granule neurons via the PI3K/Akt pathway 53 or induces apoptosis and inhibits the proliferation of several tumor cell lines. 54 Interestingly, the two MGUS BMMSCs located in the 'myeloma cluster' on genetic profiling secreted twice more GDF15 than the three MGUS BMMSCs located in the 'normal cluster'.
In agreement with the GEP of normal and MM BMMSCs, the two cell populations also showed functional differences. (i) MM BMMSCs showed a reduced matrix mineralization capability, which might be linked to the DKK1 upregulation in those cells as compared to normal BMMSCs and the downregulation of WISP-1, NPR3 and EDG-2. (ii) MM BMMSCs can support the growth of the stromal cell-dependent myeloma cell line MOLP-6 better than the normal and MGUS BMMSCs.
All the data we have presented here suggest that BMMSCs of MM patients differ from normal BMMSCs. These differences may be due to a selection by the malignant plasma cells of a BMMSC subpopulation in vivo that may favor the malignant clone growth. We cannot exclude genetic abnormalities occurring in the patients' BMMSCs themselves, but no gross abnormalities could be found by conventional genetic analysis. Finally, this specific MM BMMSC genetic profile could be characteristic of a population at increased risk for monoclonal gamopathy. Of note, genes for MGUS BMMSCs could be classified into normal or MM clusters. Of major interest will be investigation of whether patients with MGUS with an MMspecific BMMSC genetic profile are at increased risk for MM.
In conclusion, our study reveals that BMMSCs from patients with MM show a specific gene expression profile, with a differential expression of genes coding for proteins involved in MM cell growth, angiogenesis and osteoblast differentiation. Thus, these BMMSCs could create a very efficient niche to support the survival and proliferation of the myeloma stem cells and protect them from chemotherapy-induced apoptosis.
